Key Questions on PARP Inhibitors in Ovarian Cancer: Experts Evaluate the Latest Evidence

Please note: You must be registered to attend the 2021 ESMO Gynaecological Cancers Virtual Congress to attend this symposium.


*Date and Time: 25/6/2021, 16:35 - 17:35 CEST

Global experience using PARP inhibitors in treatment of ovarian cancer

Which patient and disease factors influence the choice of PARP inhibitor and whether to use them in combination?

How do you approach the use of PARP inhibitors in practice?

How can we proactively manage PARP inhibitor–related adverse events to improve quality of life for patients?

Summary, Final Thoughts and Q&A


Date / Time
Event Details


Jonathan Ledermann, MD, FRCP, FMed Sci

Professor of Medical Oncology
CRUK and UCL Cancer Trials Centre
UCL Cancer Institute
Honorary Consultant in Medical Oncology
Cancer Services
UCL Hospitals
London, United Kingdom

Frederik Marmé, MD PhD

Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg

Prof Isabelle Ray Coquard

Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Goal Statement
The goal of this activity is to educate global gynecologic oncologists, medical oncologists, and other healthcare professionals about the recent developments in the use of PARP inhibitors in the treatment of ovarian cancer.

Target Audience
This educational program is intended for global gynecologic oncologists, medical oncologists, and other healthcare professionals who care for patients with ovarian cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate available long-term follow-up data from clinical trials investigating the use of PARP inhibitors in the management of ovarian cancer
  • Apply new clinical findings in a clinical context and understand their therapeutic implications to optimize outcomes for patients with ovarian cancer
  • Identify patients with ovarian cancer most likely to benefit from PARP inhibitor therapy as single agents or in combination
  • Compare and contrast the toxicities associated with PARP inhibitors commonly used in therapy for ovarian cancer, and understand the available supportive management strategies
  • Discuss with patients and colleagues ongoing clinical studies of PARP inhibitor–based treatment in ovarian cancer


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.